Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (symbol: GH) is a pioneering biotechnology company headquartered in Redwood City, California. The company specializes in liquid-based cancer tests, providing innovative diagnostic tools for both clinical and research purposes. Guardant Health is renowned for its comprehensive liquid biopsy solutions, which offer non-invasive methods to access and sequence tumor DNA.
The company's flagship products include:
- Guardant360 LDT: A liquid biopsy test that assists in treatment selection for advanced-stage cancer patients.
- Guardant360 CDx: An FDA-approved companion diagnostic for several targeted therapies, ensuring precise treatment plans.
- Guardant OMNI: A broad gene panel designed for immuno-oncology research, aiding in the understanding of cancer's genetic underpinnings.
- Reveal: Launched in 2021, this tumor-agnostic molecular residual disease (MRD) test helps monitor cancer recurrence or residual disease at the molecular level.
- Shield: Introduced in 2022, this lab-developed test offers a non-invasive screening option for colorectal cancer (CRC).
Guardant Health's cutting-edge technologies have been widely adopted by thousands of oncologists globally, benefiting tens of thousands of advanced cancer patients. The company has made significant strides in early cancer detection, with ongoing projects that promise to deliver profound impacts on patient care.
Financially, Guardant Health has raised over $500 million from prestigious investors such as Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank. This substantial backing underscores the confidence in Guardant's potential to revolutionize cancer diagnostics and treatment.
In addition to its product offerings, Guardant Health provides research development services, including regulatory approval consultancy and clinical trial referrals. These services are designed to support the seamless integration of their diagnostic tools into clinical practice and research settings.
Stay updated with the latest news and developments about Guardant Health, Inc. as the company continues to push the boundaries of cancer diagnostics and treatment.
Guardant Health (Nasdaq: GH) reported findings from a study in JCO Precision Oncology demonstrating that its Guardant360 liquid biopsy detects 23.6% more actionable mutations compared to tissue biopsies for advanced non-small cell lung cancer (NSCLC). In a cohort of 186 patients, the liquid biopsy showed similar treatment responses and progression-free survival. The study advocates for a 'blood-first' approach, addressing challenges like insufficient tissue samples which affect 30% of patients. CEO Helmy Eltoukhy emphasized the need for broader adoption of liquid biopsies following recent FDA approval for the Guardant360 CDx test.
Guardant Health, Inc. (Nasdaq: GH) and Vall d’Hebron Institute of Oncology (VHIO) have formed a partnership to establish liquid biopsy testing services at VHIO's facility in Barcelona, Spain. This service aims to enhance access to genomic testing for cancer patients, starting with private patients and expanding to the public healthcare system. The partnership will support clinical trial eligibility assessments and accelerate cancer therapeutics research. Guardant Health's tests are backed by extensive clinical evidence and have received both CE mark and U.S. FDA approvals.
Guardant Health (Nasdaq: GH) will showcase significant data on its blood tests at the virtual 2021 ASCO Gastrointestinal Cancers Symposium from January 15-17, 2021. The presentations will focus on the clinical utility of Guardant’s liquid biopsy technology in screening and treating colorectal cancer. CEO Helmy Eltoukhy emphasized the importance of these tests in tracking treatment responses and early detection of cancer recurrence. Notable highlights include the Guardant Reveal™ test and the LUNAR-2 ECLIPSE trial aimed at early detection in average-risk adults.
Guardant Health (Nasdaq: GH) announced its participation in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11 at 7:50 a.m. PT / 10:50 a.m. ET. The event will feature a presentation by the company's management, accessible via a live and archived webcast on their website. Guardant Health specializes in precision oncology, offering blood tests and analytics that enhance cancer care. Their platforms, including Guardant360® and GuardantOMNI®, focus on advanced cancer treatment and early detection strategies.
Guardant Health, Inc. (Nasdaq: GH) has appointed Michael Bell as its new Chief Financial Officer (CFO), effective January 5, 2021. He succeeds Derek Bertocci, who retired after four years with the company. Bell brings over 25 years of finance experience from companies such as CareDx and Novartis Diagnostics. CEO Helmy Eltoukhy emphasized Bell's capability to enhance the company's financial operations and support its goal of transforming cancer care. Guardant Health specializes in precision oncology through proprietary blood tests and advanced analytics.
Guardant Health, Inc. (Nasdaq: GH) presented new findings at the 2020 Virtual San Antonio Breast Cancer Symposium, showcasing its GuardantINFORM™ platform. This tool provides critical insights into treatment responses in patients with ER-positive, HER-2 negative metastatic breast cancer, emphasizing the issue of treatment resistance. Key abstracts revealed molecular tumor evolution and resistance mechanisms. With over 135,000 patient data points in its database, GuardantINFORM aims to enhance targeted drug development and clinical trials in oncology.
Guardant Health has priced an offering of $1 billion in 0% convertible senior notes due 2027, set to settle on November 19, 2020. The notes will not accrue interest and have an initial conversion rate of 7.1523 shares per $1,000, representing a conversion price of around $139.82, a 34% premium over its recent stock price. The company expects net proceeds of approximately $984.3 million, intended for corporate purposes, including research and development and potential acquisitions. Additionally, capped call transactions are in place to reduce dilution from the notes' conversion.
Guardant Health (Nasdaq: GH) announced a private offering of $1 billion in convertible senior notes due 2027, with an additional $150 million option for initial purchasers. The notes will mature on November 15, 2027, and can be converted into cash or stock. Proceeds will fund capped call transactions and general corporate purposes, including R&D and potential acquisitions. This offering is subject to market conditions, and the notes are not registered under the Securities Act. Guardant Health is a leader in precision oncology, focusing on innovative blood tests for cancer detection.
Guardant Health (GH) reported a 23% revenue increase to $74.6 million for Q3 2020, driven by a 16% rise in precision oncology revenue ($60.4 million). Development services surged 63% to $14.2 million. Clinical test volume rose 28% to 16,950, but biopharmaceutical tests fell 42% to 3,071. The company received FDA approval for Guardant360® CDx, the first liquid biopsy for comprehensive cancer profiling. Despite a gross profit rise to $53.4 million, operating expenses ballooned 113% to $127.6 million, leading to a net loss of $77.7 million ($0.78 per share). Guidance for 2020 remains unprovided due to COVID-19 uncertainties.
Guardant Health, Inc. (Nasdaq: GH) will release its third-quarter 2020 financial results on November 5, 2020, after market closure. A conference call will follow at 1:30 p.m. PT. Investors can access the live audio webcast in the 'Investors' section of the company website. Guardant Health specializes in precision oncology, providing advanced blood tests like Guardant360 and GuardantOMNI to improve cancer patient outcomes and reduce healthcare costs. The company focuses on all cancer care stages, including early detection and selection of treatments for advanced cancer patients.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
What does Guardant Health, Inc. specialize in?
What are the main products offered by Guardant Health?
What is Guardant360 CDx?
How does Guardant Health support cancer research?
What is the significance of the Reveal test?
What is the purpose of the Shield test?
Who are some of the major investors in Guardant Health?
Where is Guardant Health, Inc. headquartered?
What is the Guardant360 LDT test used for?
How does Guardant Health contribute to early cancer detection?
